843 related articles for article (PubMed ID: 11799102)
1. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril.
Nussberger J; Wuerzner G; Jensen C; Brunner HR
Hypertension; 2002 Jan; 39(1):E1-8. PubMed ID: 11799102
[TBL] [Abstract][Full Text] [Related]
2. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans.
Fisher ND; Jan Danser AH; Nussberger J; Dole WP; Hollenberg NK
Circulation; 2008 Jun; 117(25):3199-205. PubMed ID: 18559696
[TBL] [Abstract][Full Text] [Related]
3. Comparison of blood pressure and angiotensin responses to the renin inhibitor Ro 42-5892 and the angiotensin converting enzyme inhibitor enalapril in essential hypertension.
van den Meiracker AH; Admiraal PJ; Derkx FH; Kleinbloesem C; Man in 't Veld AJ; van Brummelen P; Mulder P; Schalekamp MA
J Hypertens; 1993 Aug; 11(8):831-8. PubMed ID: 8228207
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the angiotensin II antagonist UP269-6 with the angiotensin converting enzyme inhibitor enalapril in normotensive volunteers challenged with angiotensin I.
Inglessis N; Nussberger J; Hagmann M; Hiesse-Provost O; Insuasty J; Reid J; Ménard J; Brunner HR
J Cardiovasc Pharmacol; 1995 Jun; 25(6):986-93. PubMed ID: 7564346
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100). Comparison with enalapril.
Hollenberg NK
Curr Hypertens Rep; 2002 Aug; 4(4):269-70. PubMed ID: 12168611
[No Abstract] [Full Text] [Related]
6. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives.
Azizi M; Chatellier G; Guyene TT; Murieta-Geoffroy D; Ménard J
Circulation; 1995 Aug; 92(4):825-34. PubMed ID: 7641363
[TBL] [Abstract][Full Text] [Related]
7. Additive effects of losartan and enalapril on blood pressure and plasma active renin.
Azizi M; Guyene TT; Chatellier G; Wargon M; Ménard J
Hypertension; 1997 Feb; 29(2):634-40. PubMed ID: 9040450
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the oral angiotensin II receptor antagonist UP 269-6 or enalapril 20 mg on blood pressure and neurohormonal effects in salt-deplete man.
McIntyre M; MacFadyen RJ; Meredith PA; Menard J; Brunner HR; Insuasty J; Reid JL
J Cardiovasc Pharmacol; 1995 Jun; 25(6):994-1000. PubMed ID: 7564347
[TBL] [Abstract][Full Text] [Related]
9. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats.
Wood JM; Schnell CR; Cumin F; Menard J; Webb RL
J Hypertens; 2005 Feb; 23(2):417-26. PubMed ID: 15662231
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?
Athyros VG; Mikhailidis DP; Kakafika AI; Tziomalos K; Karagiannis A
Expert Opin Pharmacother; 2007 Apr; 8(5):529-35. PubMed ID: 17376010
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption.
Azizi M; Ménard J; Bissery A; Guyenne TT; Bura-Rivière A; Vaidyanathan S; Camisasca RP
J Am Soc Nephrol; 2004 Dec; 15(12):3126-33. PubMed ID: 15579516
[TBL] [Abstract][Full Text] [Related]
12. Direct inhibition of renin as a cardiovascular pharmacotherapy: focus on aliskiren.
Sepehrdad R; Frishman WH; Stier CT; Sica DA
Cardiol Rev; 2007; 15(5):242-56. PubMed ID: 17700383
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
Rao MS
J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
[TBL] [Abstract][Full Text] [Related]
14. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study.
Krum H; Massie B; Abraham WT; Dickstein K; Kober L; McMurray JJ; Desai A; Gimpelewicz C; Kandra A; Reimund B; Rattunde H; Armbrecht J;
Eur J Heart Fail; 2011 Jan; 13(1):107-14. PubMed ID: 21169387
[TBL] [Abstract][Full Text] [Related]
15. Maximum renal responses to renin inhibition in healthy study participants: VTP-27999 versus aliskiren.
Barkoudah E; van Thiel BS; Fisher ND; Gregg RA; Danser AH; Moukarbel GV; Hollenberg NK
J Hypertens; 2016 May; 34(5):935-41. PubMed ID: 26882043
[TBL] [Abstract][Full Text] [Related]
16. Renin inhibition ameliorates renal damage through prominent suppression of both angiotensin I and II in human renin angiotensinogen transgenic mice with high salt loading.
Yoshida S; Ishizawa K; Ayuzawa N; Ueda K; Takeuchi M; Kawarazaki W; Fujita T; Nagase M
Clin Exp Nephrol; 2014 Aug; 18(4):593-9. PubMed ID: 24154707
[TBL] [Abstract][Full Text] [Related]
17. [The future of renin inhibition].
Uresin AY; Baran E
Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological demonstration of the additive effects of angiotensin-converting enzyme inhibition and angiotensin II antagonism in sodium depleted healthy subjects.
Azizi M; Guyene TT; Chatellier G; Ménard J
Clin Exp Hypertens; 1997; 19(5-6):937-51. PubMed ID: 9247766
[TBL] [Abstract][Full Text] [Related]
19. Renal effects of angiotensin I-receptor blockade and angiotensin convertase inhibition in man.
Schmitt F; Natov S; Martinez F; Lacour B; Hannedouche TP
Clin Sci (Lond); 1996 Mar; 90(3):205-13. PubMed ID: 8777826
[TBL] [Abstract][Full Text] [Related]
20. Differing early blood pressure and renin-angiotensin system responses to the first dose of angiotensin-converting enzyme inhibitors in congestive heart failure.
Squire IB; MacFayden RJ; Reid JL; Devlin A; Lees KR
J Cardiovasc Pharmacol; 1996 May; 27(5):657-66. PubMed ID: 8859935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
